Curis, Inc. Presents Data on PI3K and HDAC Inhibitor CUDC-907 at the 2011 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer Symposium

Published: Nov 16, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in a poster presentation at the 2011 AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California. The poster presentation was titled “Anti-tumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models” and was presented by Rudi Bao, M.D., Ph.D., Curis’ Senior Director of Oncology.

Back to news